Sign in Subscribe
Cancer

Fragment-Based Immune Cell Engager Antibodies: A Promising Approach in Treating Autoimmunity and Cancer

Strategic Insights

— 2 min read

Researchers at Rutgers University - The State University of New Jersey have made significant progress in the development of fragment-based immune cell engager antibodies, which have shown promise in treating various cancers, infectious, and autoimmune diseases. According to a recent review, these antibodies have been designed to target specific proteins, leading to improved treatment outcomes. However, clinical outcomes have been mixed, and understanding the underlying reasons for success and failures is crucial. A comprehensive review of clinical and translational studies aims to fill this knowledge gap, providing valuable insights for the development of these innovative therapies.

Key Takeaways:

  • Fragment-based immune cell engager antibodies have been designed to target specific proteins, offering a promising approach in treating various diseases.
  • These antibodies have shown promise in preclinical development, with some studies indicating improved treatment outcomes.
  • However, clinical outcomes have been mixed, with successes and failures attributed to various factors, including disease complexity and treatment modalities.
  • The review aims to provide clinically driven insights, accompanied by translational and mechanistic studies, on the current landscape of fragment-based immune cell engager antibodies.
  • Mohammad Massumi and Ge Yang, researchers at Rutgers University - The State University of New Jersey, have contributed to this research, highlighting the potential of fragment-based antibodies in treating autoimmunity and cancer.
  • The review provides a comprehensive analysis of clinical and translational studies, offering valuable lessons and insights for the development of these innovative therapies.

Statistics:

  • 14(3):52 - The issue number and page where the research article "Fragment-Based Immune Cell Engager Antibodies in Treatment of Cancer, Infectious and Autoimmune Diseases: Lessons and Insights from Clinical and Translational Studies" was published in Antibodies.
  • 2025 - The year when the research article "Fragment-Based Immune Cell Engager Antibodies in Treatment of Cancer, Infectious and Autoimmune Diseases: Lessons and Insights from Clinical and Translational Studies" was published.
  • MDPI AG - The publisher of the journal Antibodies, where the research article was published.
  • https://doi-org.sdpl.idm.oclc.org/10.3390/antib14030052 - The DOI link to the free version of the research article available at https://doi-org.sdpl.idm.oclc.org/10.3390/antib14030052.

Sources:

  • NewsRx. Rutgers University - The State University of New Jersey Researchers Update Current Data on Autoimmunity (Fragment-Based Immune Cell Engager Antibodies in Treatment of Cancer, Infectious and Autoimmune Diseases: Lessons and Insights from ...). Clinical Trials Week. October 13, 2025; p 82.
  • Fragment-Based Immune Cell Engager Antibodies in Treatment of Cancer, Infectious and Autoimmune Diseases: Lessons and Insights from Clinical and Translational Studies. Antibodies, 2025,14(3):52. (Antibodies - http://www.mdpi.com/journal/antibodies).
  • Rutgers University - The State University of New Jersey, Piscataway, New Jersey, United States.

Read more